(3,3-Dimethyl-2-oxobutyl)-trimethylazanium

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3,3-Dimethyl-2-oxobutyl)-trimethylazanium
• 化学式: C9H20NO+
• 分子量: 158.26
• InChiKey: OXZSRJFHTKJTGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20140330006A1

  公开（公告）日：2014-11-06

  Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位间连接和/或修改的3'和/或5'-末端基团的功能修饰寡核苷酸类似物。所公开的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病是有用的。
• OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
  申请人：Hanson Gunnar J.

  公开号：US20120065169A1

  公开（公告）日：2012-03-15

  Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位连接和/或修改的3'和/或5'-末端基团的寡核苷酸类似物。所披露的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病非常有用。
• PEPTIDE OLIGONUCLEOTIDE CONJUGATES
  申请人：Hanson Gunnar J.

  公开号：US20120289457A1

  公开（公告）日：2012-11-15

  Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了与载体肽共轭的寡核苷酸类似物。所公开的化合物可用于治疗各种疾病，例如抑制蛋白质表达或校正异常的mRNA剪接产物可产生有益的治疗效果的疾病。
• COMPOUNDS FOR FLUORESCENCE IMAGING
  申请人：Lange Norbert

  公开号：US20100278745A1

  公开（公告）日：2010-11-04

  Methods and compositions involving enzyme-activatable fluorophore polymer imaging agents for photodetection of specific tissues and/or human diseases and disorders are provided. In certain embodiments, the imaging agent comprises a hydrophilic polymer backbone (e.g., poly(L)lysine), a hydrophobic fluorophore, and a hydrophilic solubilizing agent. The solubilizing agent may comprise a quarternary ammonium group (e.g., a 1-methylnicotinic group) to enhance self-quenching of the fluorophore. Various methods for the generation and purification of imaging agents are also provided, including methods involving solid phase probe extraction or ion exchange purification.
• COMBINATION OF A 17 ALPHA-HYDROXYLASE/C17, 20-LYASE INHIBITOR WITH AN ADDITIONAL THERAPEUTIC AGENT
  申请人：Casebier David

  公开号：US20110319369A1

  公开（公告）日：2011-12-29

  The invention describes methods of treating cancer in which a therapeutically-effective amount of a 17α-hydroxylase/C 17,20 -lyase inhibitor is administered to a subject in need thereof, including a subject with a refractory cancer and/or a subject currently undergoing another cancer treatment, wherein the 17α-hydroxylase/C 17,20 -lyase inhibitor is administered in combination with a therapeutically-effective amount of at least one additional therapeutic agent, including, but not limited to, another anti-cancer agent or a steroid.